$114.66 Million in Sales Expected for BioTelemetry Inc (NASDAQ:BEAT) This Quarter

Brokerages expect that BioTelemetry Inc (NASDAQ:BEAT) will announce sales of $114.66 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for BioTelemetry’s earnings. The lowest sales estimate is $110.71 million and the highest is $118.60 million. BioTelemetry reported sales of $103.60 million in the same quarter last year, which indicates a positive year over year growth rate of 10.7%. The business is expected to announce its next earnings results on Thursday, February 20th.

According to Zacks, analysts expect that BioTelemetry will report full-year sales of $437.78 million for the current financial year. For the next financial year, analysts expect that the firm will report sales of $491.70 million, with estimates ranging from $489.09 million to $494.30 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for BioTelemetry.

BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.02. BioTelemetry had a net margin of 8.98% and a return on equity of 22.27%. The business had revenue of $111.30 million for the quarter, compared to the consensus estimate of $111.19 million. During the same period in the previous year, the firm earned $0.53 EPS. The business’s revenue for the quarter was up 11.3% on a year-over-year basis.

A number of research firms recently commented on BEAT. BidaskClub upgraded shares of BioTelemetry from a “strong sell” rating to a “sell” rating in a report on Friday, October 18th. Lake Street Capital reiterated a “buy” rating and issued a $80.00 target price (down from $90.00) on shares of BioTelemetry in a report on Wednesday. ValuEngine upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Sidoti dropped their target price on shares of BioTelemetry from $95.00 to $87.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Finally, Zacks Investment Research downgraded shares of BioTelemetry from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. BioTelemetry currently has an average rating of “Buy” and a consensus target price of $71.83.

In other news, SVP Peter Ferola sold 44,276 shares of BioTelemetry stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $39.03, for a total value of $1,728,092.28. Following the transaction, the senior vice president now directly owns 19,622 shares of the company’s stock, valued at $765,846.66. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 6.50% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in BEAT. Amundi Pioneer Asset Management Inc. grew its position in BioTelemetry by 34.4% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 45,700 shares of the medical research company’s stock valued at $2,862,000 after purchasing an additional 11,700 shares in the last quarter. Cortina Asset Management LLC grew its position in BioTelemetry by 21.3% during the second quarter. Cortina Asset Management LLC now owns 143,816 shares of the medical research company’s stock valued at $6,925,000 after purchasing an additional 25,280 shares in the last quarter. New England Research & Management Inc. purchased a new position in BioTelemetry during the second quarter valued at approximately $549,000. Scout Investments Inc. grew its position in BioTelemetry by 65.1% during the second quarter. Scout Investments Inc. now owns 208,760 shares of the medical research company’s stock valued at $10,052,000 after purchasing an additional 82,281 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in BioTelemetry during the second quarter valued at approximately $307,000. 91.19% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ BEAT traded up $1.25 during midday trading on Tuesday, reaching $45.80. The company’s stock had a trading volume of 309,700 shares, compared to its average volume of 463,447. The company has a current ratio of 2.19, a quick ratio of 2.09 and a debt-to-equity ratio of 0.54. The company has a 50 day moving average price of $40.53 and a 200 day moving average price of $45.18. BioTelemetry has a one year low of $37.07 and a one year high of $80.92. The company has a market cap of $1.46 billion, a price-to-earnings ratio of 23.61, a price-to-earnings-growth ratio of 2.18 and a beta of 1.31.

BioTelemetry Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

See Also: Trade Deficit

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.